de BlackRock Vertex Pharmaceuticals VRTX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 12 mil M | Comprar |
24,109,373
+139,856
| +0.6% | +USD 62 M | 0.18% | 85 |
|
|
2026
Q1 | USD 10.7 mil M | Comprar |
23,969,517
+217,528
| +0.9% | +USD 101 M | 0.19% | 89 |
|
|
2025
Q4 | USD 10.8 mil M | Comprar |
23,751,989
+1,498,942
| +7% | +USD 646 M | 0.18% | 92 |
|
|
2025
Q3 | USD 8715 M | Comprar |
22,253,047
+381,102
| +2% | +USD 159 M | 0.15% | 107 |
|
|
2025
Q2 | USD 9737 M | Comprar |
21,871,945
+89,012
| +0.4% | +USD 41 M | 0.19% | 94 |
|
|
2025
Q1 | USD 10.6 mil M | Vender |
21,782,933
-42,537
| -0.2% | -USD 19.8 M | 0.22% | 77 |
|
|
2024
Q4 | USD 8789 M | Comprar |
21,825,470
+37,924
| +0.2% | +USD 17.6 M | 0.18% | 91 |
|
|
2024
Q3 | USD 10.1 mil M | Comprar |
21,787,546
+475,302
| +2% | +USD 228 M | 0.21% | 78 |
|
|
2024
Q2 | USD 9989 M | Vender |
21,312,244
-648,443
| -3% | -USD 281 M | 0.23% | 72 |
|
|
2024
Q1 | USD 9180 M | Comprar |
21,960,687
+79,484
| +0.4% | +USD 33.6 M | 0.21% | 77 |
|
|
2023
Q4 | USD 8903 M | Vender |
21,881,203
-704,023
| -3% | -USD 260 M | 0.23% | 71 |
|
|
2023
Q3 | USD 7854 M | Vender |
22,585,226
-235,200
| -1% | -USD 82.3 M | 0.23% | 72 |
|
|
2023
Q2 | USD 8031 M | Vender |
22,820,426
-1,086,177
| -5% | -USD 366 M | 0.22% | 73 |
|
|
2023
Q1 | USD 7532 M | Vender |
23,906,603
-334,834
| -1% | -USD 100 M | 0.22% | 82 |
|
|
2022
Q4 | USD 7000 M | Vender |
24,241,437
-1,001,623
| -4% | -USD 305 M | 0.22% | 84 |
|
|
2022
Q3 | USD 7309 M | Comprar |
25,243,060
+105,908
| +0.4% | +USD 30.5 M | 0.25% | 71 |
|
|
2022
Q2 | USD 7083 M | Comprar |
25,137,152
+1,220,898
| +5% | +USD 327 M | 0.23% | 77 |
|
|
2022
Q1 | USD 6241 M | Vender |
23,916,254
-28,677
| -0.1% | -USD 6.81 M | 0.17% | 102 |
|
|
2021
Q4 | USD 5258 M | Comprar |
23,944,931
+397,036
| +2% | +USD 77.2 M | 0.13% | 130 |
|
|
2021
Q3 | USD 4271 M | Comprar |
23,547,895
+187,806
| +0.8% | +USD 36.7 M | 0.12% | 142 |
|
|
2021
Q2 | USD 4710 M | Vender |
23,360,089
-884,024
| -4% | -USD 185 M | 0.13% | 132 |
|
|
2021
Q1 | USD 5210 M | Vender |
24,244,113
-24,782
| -0.1% | -USD 5.44 M | 0.15% | 112 |
|
|
2020
Q4 | USD 5736 M | Vender |
24,268,895
-906,646
| -4% | -USD 208 M | 0.18% | 94 |
|
|
2020
Q3 | USD 6851 M | Vender |
25,175,541
-332,357
| -1% | -USD 91.7 M | 0.25% | 67 |
|
|
2020
Q2 | USD 7405 M | Comprar |
25,507,898
+3,181,850
| +14% | +USD 863 M | 0.3% | 60 |
|
|
2020
Q1 | USD 5312 M | Comprar |
22,326,048
+1,209,227
| +6% | +USD 277 M | 0.26% | 70 |
|
|
2019
Q4 | USD 4624 M | Comprar |
21,116,821
+42,700
| +0.2% | +USD 8.64 M | 0.18% | 105 |
|
|
2019
Q3 | USD 3570 M | Comprar |
21,074,121
+365,452
| +2% | +USD 64.7 M | 0.15% | 125 |
|
|
2019
Q2 | USD 3798 M | Comprar |
20,708,669
+532,371
| +3% | +USD 93.1 M | 0.16% | 108 |
|
|
2019
Q1 | USD 3711 M | Comprar |
20,176,298
+568,488
| +3% | +USD 105 M | 0.17% | 107 |
|
|
2018
Q4 | USD 3249 M | Vender |
19,607,810
-328,033
| -2% | -USD 56.8 M | 0.16% | 109 |
|
|
2018
Q3 | USD 3842 M | Comprar |
19,935,843
+625,328
| +3% | +USD 111 M | 0.17% | 110 |
|
|
2018
Q2 | USD 3282 M | Vender |
19,310,515
-577,530
| -3% | -USD 89.5 M | 0.15% | 121 |
|
|
2018
Q1 | USD 3241 M | Comprar |
19,888,045
+478,972
| +2% | +USD 78.2 M | 0.15% | 125 |
|
|
2017
Q4 | USD 2909 M | Vender |
19,409,073
-326,848
| -2% | -USD 48.4 M | 0.14% | 138 |
|
|
2017
Q3 | USD 3001 M | Comprar |
19,735,921
+329,940
| +2% | +USD 49.7 M | 0.15% | 132 |
|
|
2017
Q2 | USD 2501 M | Comprar |
19,405,981
+159,601
| +0.8% | +USD 19.2 M | 0.13% | 152 |
|
|
2017
Q1 | USD 2105 M | Comprar |
19,246,380
+18,558,874
| +2,699% | +USD 1634 M | 0.12% | 177 |
|
|
2016
Q4 | USD 50.6 M | Vender |
687,506
-59,727
| -8% | -USD 4.86 M | 0.07% | 311 |
|
|
2016
Q3 | USD 65.2 M | Comprar |
747,233
+7,843
| +1% | +USD 741 k | 0.09% | 243 |
|
|
2016
Q2 | USD 63.6 M | Comprar |
739,390
+60,800
| +9% | +USD 5.25 M | 0.1% | 234 |
|
|
2016
Q1 | USD 53.9 M | Vender |
678,590
-34,032
| -5% | -USD 3.08 M | 0.09% | 261 |
|
|
2015
Q4 | USD 89.7 M | Comprar |
712,622
+23,209
| +3% | +USD 2.8 M | 0.13% | 178 |
|
|
2015
Q3 | USD 71.8 M | Vender |
689,413
-69,169
| -9% | -USD 8.89 M | 0.11% | 213 |
|
|
2015
Q2 | USD 93.7 M | Vender |
758,582
-195,798
| -21% | -USD 24.7 M | 0.14% | 176 |
|
|
2015
Q1 | USD 113 M | Comprar |
954,380
+81,587
| +9% | +USD 9.8 M | 0.16% | 150 |
|
|
2014
Q4 | USD 104 M | Comprar |
872,793
+198,308
| +29% | +USD 22.3 M | 0.15% | 152 |
|
|
2014
Q3 | USD 75.8 M | Comprar |
674,485
+126,558
| +23% | +USD 12 M | 0.11% | 194 |
|
|
2014
Q2 | USD 51.9 M | Vender |
547,927
-71,465
| -12% | -USD 5.01 M | 0.08% | 278 |
|
|
2014
Q1 | USD 43.8 M | Vender |
619,392
-73,058
| -11% | -USD 5.79 M | 0.07% | 288 |
|
|
2013
Q4 | USD 51.4 M | Comprar |
692,450
+130,085
| +23% | +USD 9.06 M | 0.08% | 249 |
|
|
2013
Q3 | USD 42.6 M | Comprar |
562,365
+431,507
| +330% | +USD 34.3 M | 0.08% | 263 |
|
|
2013
Q2 | USD 10.5 M | Comprar |
+130,858
| Nuevas | +USD 9.6 M | 0.02% | 585 |
|
Otros fondos que tienen VRTX en su cartera
Posición de BlackRock en VRTX: resumen de T2 2026
BlackRock aumentó su participación en Vertex Pharmaceuticals (VRTX) en 0.58% durante T2 2026, al comprar aproximadamente USD 62 M y elevar la posición a 24,109,373 acciones con un valor de USD 12 mil M. La posición representa 0.18% de la cartera y ocupa el puesto #85.
BlackRock reportó por primera vez una posición en VRTX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,765 fondos que sigue Wall St. Rank mantienen una posición en VRTX.
- Al cierre de T2 2026, BlackRock tenía 24,109,373 acciones de Vertex Pharmaceuticals con un valor de USD 12 mil M.
- BlackRock compró 139,856 acciones de Vertex Pharmaceuticals en T2 2026, por un monto estimado de USD 62 M.
- Vertex Pharmaceuticals representó 0.18% de la cartera de BlackRock en T2 2026 y fue su posición número 85.
- BlackRock reportó por primera vez una posición en Vertex Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,765 fondos que sigue Wall St. Rank tenían Vertex Pharmaceuticals en cartera.
Según el Informe 13F de BlackRock correspondiente a T2 2026, presentado el 7 ago 2026.